Refine by
Genetic Disease Articles & Analysis
115 news found
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive formation of fluid-filled cysts in the kidneys, often leading to complications, including hypertension, kidney stones, urinary tract infections, and eventually kidney failure. ...
Gene therapy for glaucoma is a promising field of research focused on developing treatments to address the underlying causes of the disease, potentially offering more effective and long-lasting solutions than current options. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. ...
This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. Changes in glycoprotein abundance and ...
The applications of WGS are vast, impacting fields such as disease research, drug discovery, personalized medicine, food safety, agriculture, and pharmacy. ...
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. ...
Recognizing the dire need for accelerated research in the field of rare diseases, the comprehensive gene therapy development solutions aim to overhaul the traditional slow and resource-intensive process of genetic research. ...
This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise genetic information plays a pivotal role. ...
To address this challenge, CD Genomics has developed a comprehensive Mitochondrial Diseases Panel Sequencing service that enables researchers to accurately identify mitochondrial DNA and nuclear DNA mutations and obtain a comprehensive view of the patient’s genetic makeup. ...
Application of induced pluripotent technology allows to fabricate tissues in diseased states, e.g., hereditary cardiac diseases, cardiac fibrosis, cancer and orphan diseases. ...
Those diagnosed before 50 with advanced-stage PC may have a genetic predisposition for the disease. For many young men, the prognosis is often dire, and the progression is more aggressive than in older peers at a similar stage and grade. ...
It takes into consideration an individual’s genetic makeup, lifestyle factors such as diet, and environmental influences when creating treatment plans to best meet their needs. ...
TMAs lesions can be associated with many diseases and some genetic disorders linked to aHUS. Molecular diagnoses, in particular in genes associated with alternative complement pathway regulation, make it possible to identify patients that suffer from this condition as well as informing on possible therapeutic options for TMA/aHUS. ...
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. ...
[i] The most common form of the disease is caused by a genetic mutation of the ABCA4 gene, ultimately leading to vision loss. Currently, there are no treatments for Stargardt disease available. “We are excited that our product candidate VG801 for Stargardt disease is ready for IND-enabling studies. ...
This collaboration could extend the reach of gene editing for liver and lung disease targets. “AskBio’s pioneering gene editing technology is a powerful complement to our modular SORT LNP genetic medicines platform, which enables the precise delivery of a wide variety of genetic cargoes to specific organs and cells, including large, ...
ByBayer AG
The company is pleased to announce the launch of the CRISPR off-target analysis service to help researchers optimize the CRISPR system, reduce off-target rates, and further explore genetic information related to human health. In recent years, CRISPR technology has significantly promoted the innovation of gene therapy for blood diseases, tumors, ...
The human genome has approximately 180,000 exomes, which are approximately 30 Mb in length, and the majority of disease-causing mutations among monogenic genetic diseases have been reported to be concentrated in the exome region. ...
Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to serve genetically defined patients suffering from cancer and autoimmune diseases, today announced that Syed Kazmi, Chief Executive Officer, will be making a business update presentation and meeting with institutional ...
WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and ...